Stricter Versus Usual Blood Pressure Control After Stroke Clot Removal
Compares two blood pressure targets in adults after clot removal for stroke.
Plain-language title generated from the registry record
Registry title: Intensive Versus Conventional Blood Pressure Control Following Stroke Thrombectomy
Key facts
- Where
- Suzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden stroke in the front part of the brain who had a successful clot-removal procedure (thrombectomy) and whose blood pressure stays high afterwards.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Sudden (acute) stroke from a blocked artery in the front part of the brain. Clot removal started less than 24 hours after symptoms began. The blocked vessel was successfully reopened (mTICI 2b or better). NIHSS score 30 or lower. ASPECTS score 6 or higher.
- Earlier treatment
- Must have had a successful endovascular thrombectomy (clot removal through a blood vessel). Must not have joined another interventional trial in the past 3 months.
- Biomarker or test result
- Systolic blood pressure of 140 mmHg or higher on at least two measurements more than 10 minutes apart, within 3 hours of the vessel being reopened.
Main reasons for not taking part
- Disability before the stroke (mRS above 2)
- Brain tumour or vascular malformation
- Severe liver or kidney problems, or on dialysis
- Serious illness with life expectancy under 6 months
- Breastfeeding women
Read by machine on 12 November 2026.
Where in China
- The Fourth Affiliated Hospital of Soochow UniversitySuzhou, ChinaContact: Yonggang Hao, DoctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hao Yonggang
- Trial code
- NCT07350564
- Record updated
- 20 January 2026
- Original description
This clinical trial aims to investigate the safety and efficacy of intensive blood pressure lowering after successful reperfusion with thrombectomy in patients with acute anterior circulation large artery occlusive stroke. The main questions it aims to answer are:Read full original descriptionShow less
Intensive Blood Pressure Control After Endovascular Thrombectomy for Acute Embolic Stroke (INTENSE): a Multicentre, Open-label, Blinded-endpoint, Randomised Controlled Trial
This clinical trial aims to investigate the safety and efficacy of intensive blood pressure lowering after successful reperfusion with thrombectomy in patients with acute anterior circulation large artery occlusive stroke. The main questions it aims to answer are:
What is the optimal blood pressure range after revascularization with thrombectomy in patients with cerebral embolism? Can intensive blood pressure lowering improve outcomes in cerebral embolism patients following thrombectomy?
Participants will be randomly assigned to either the intervention group, which receives stricter blood pressure control (systolic blood pressure target <120 mmHg), or the control group, which follows a conventional blood pressure management approach (systolic blood pressure target 140-180 mmHg). Outcomes will be assessed during a 3-month follow-up period.
Inclusion: Age ≥ 18 years; To receive endovascular thrombectomy <24 hours after the onset of symptoms; Diagnosed with acute anterior circulation ischemic stroke; National Institutes of Health Stroke Scale (NIHSS) score ≤ 30; Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6; Computed Tomography Angiography (CTA), Magnetic Resonance Angiography (MRA), or Digital Subtraction Angiography (DSA) confirming occlusion of the intracranial internal carotid artery or M1/M2 segment of the middle cerebral artery; Successful recanalization of the occluded vessel without in-situ or proximal stenosis (modified Treatment in Cerebral Infarction, mTICI ≥ 2b); Sustained elevated systolic blood pressure (≥140 mmHg for at least two consecutive measurements, separated by >10 minutes) within 3 hours of reperfusion; Written informed consent provided by the patient or their legal representative.
Exclusion: Pre-existing stroke disability defined by a modified Rankin score (mRS) >2; Unlikely to benefit from or tolerate endovascular thrombectomy, such as severe allergic reaction to contrast agents; Failure to achieve mTICI ≥ 2b with endovascular intervention, or presence of in situ or proximal vascular stenosis; Patients with contraindications for the use of antihypertensive medications, such as allergy to components; Serious illness with life expectancy of <6 months; Any other conditions that render patients unsuitable for participation in this study or unable to complete the study process, such as psychiatric disorders, cognitive or emotional impairments, or physical conditions that hinder compliance with study procedures and follow-up; Patients with severe liver or renal dysfunction, or those receiving dialysis (severe liver dysfunction is defined as alanine aminotransferase [ALT] > 3 times the upper limit of normal or aspartate aminotransferase [AST] > 3 times the upper limit of normal; severe renal dysfunction is defined as serum creatinine > 3.0 mg/dL [265.2 μmol/L] or glomerular filtration rate [GFR] < 30 mL/min/1.73 m²); Intracranial space-occupying lesions, including brain tumors and vascular malformations; Lactating women; Participation in other interventional clinical trials within the past 3 months.